These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25675262)

  • 1. Oral depot antipsychotic drugs: time for a paradigm shift?
    Nandhra HS; Sule A
    J Ment Health; 2015 Aug; 24(4):181-2. PubMed ID: 25675262
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of depot medications in the treatment of schizophrenia.
    Davis JM
    Am J Psychiatry; 2010 Feb; 167(2):125-6. PubMed ID: 20123919
    [No Abstract]   [Full Text] [Related]  

  • 4. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.
    Brnabic AJ; Kelin K; Ascher-Svanum H; Montgomery W; Kadziola Z; Karagianis J
    Int J Clin Pract; 2011 Sep; 65(9):945-53. PubMed ID: 21849009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving treatment adherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
    Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ; Kissling W
    Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
    Citrome L
    CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are depot as effective as oral antipsychotics on first-episode psychosis?
    Orus C; Aceituno D
    Medwave; 2016 May; 16 Suppl 2():e6447. PubMed ID: 27218484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone vs. placebo for schizophrenia.
    Kripke C
    Am Fam Physician; 2010 May; 81(9):1096. PubMed ID: 20433125
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delaying time to relapse in schizophrenia. The role of long-acting injectable antipsychotics.
    Muller R
    Manag Care; 2014 Apr; 23(4 Suppl 1):2-3. PubMed ID: 25029779
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral versus depot medication in schizophrenia.
    Johnson DA
    Acta Psychiatr Scand Suppl; 1981; 291():56-64. PubMed ID: 6113735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
    Citrome L
    Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The significance of depot medication in the long-term-treatment of schizophrenia].
    Kühn KU; Wiedemann K; Hellweg R; Möller HJ
    Fortschr Neurol Psychiatr; 2014 Oct; 82(10):557-65. PubMed ID: 25299626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New advances in pharmacotherapy for early psychosis.
    Emsley R
    Early Interv Psychiatry; 2009 Sep; 3 Suppl 1():S8-12. PubMed ID: 21352195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
    Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.